## PARNAX LAB LIMITED

## (FORMERLY KRISHNA-DEEP TRADE & INVESTMENT LIMITED)

	AUDITED RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED 31.03.2013										
PART I Rs. In Lacs											
		Standalone						Consolidated			
<u> </u>		Audited		audited	Audited	Audited Audited Unaudited			Audited	Audited	
	Particulars	Current	Previous	Corresponding	Current Year	Previous	Current	Previous	-	Current Year	Previous
		Quarter Ended	Quarter ended	Quarter Ended	Ended 31.03.2013	Year 31.03.2012	Quarter Ended	Quarter ended	ng Quarter Ended	Ended 31.03.2013	Year 31.03.2012
		31.03.2013	31.12.2012	31.03.2012	31.03.2013	31.03.2012	31.03.2013	31.12.2012	31.03.2012	31.03.2013	31.03.2012
1	Income from operations										
	(a) Net sales/income from operations (Net of excise duty)	832.59	704.71	2835.52	2,590.51	5,587.88	1,497.24	1,602.73	4158.85	5,582.12	9,306.44
	(b) Other operating income	51.31	13.42	12.11	94.29	58.08	52.60	13.35	12.11	95.58	62.68
	Total income from operations (net)	883.90	718.13	2,847.63	2,684.80	5,645.96	1,549.84	1,616.08	4,170.96	5,677.70	9,369.12
2	Expenses										
	(a) Cost of materials consumed	369.53	450.21	516.66	1,486.77	2,102.59	667.81	973.20	1534.99	· ·	4,512.86
	(b) Purchases of stock-in-trade	173.50	-	2151	173.50	3,208.43	173.50	-	2151		3,208.43
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	79.80	(52.78)		116.05	(53.70)		(101.44)	97.1		(74.30)
	(d) Employee benefits expense	78.91	76.71	75.04	299.95	326.74	147.97	147.67	134.91		560.15
	(e) Depreciation and amortisation expense	18.14	18.95	19.48		77.92	48.93	48.77	47.45		189.79
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	127.87	122.19	250.8	425.84	579.17	280.09	302.75	371.94	1,035.51	1,063.19
	Total expenses	847.75	615.28	3133.15	2,576.85	6241.15	1400.01	1370.95	4337.39	5031.61	9460.12
3	Profit / (Loss) from operations before other income, finance costs and exceptional items(1-2)	36.15	102.85	(285.52)	107.95	(595.19)	149.83	245.13	(166.43)	646.09	(91.00)
4	Other Income		-	-		-	-	-	-	-	-
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	36.15	102.85	(285.52)	107.95	(595.19)	149.83	245.13	(166.43)	646.09	(91.00)
6	Finance costs	27.83	29.15	42.57	155.35	171.55	80.33	82.89	112.51	381.98	425.40
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	8.32	73.70	(328.09)	(47.40)	(766.74)	69.50	162.24	(278.94)	264.11	(516.40)
8	Exceptional Items	-	-	-	-	-	-	-	-	-	-
9	Profit / (Loss) from ordinary activities	8.32	73.70	(328.09)	(47.40)	(766.74)	69.50	162.24	(278.94)	264.11	(516.40)

	before tax (7 ± 8)										
10	Tax Expense	-	-	-	(7.92)	(241.86)	-	-	-	93.14	(236.79)
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	8.32	73.70	(328.09)	(39.48)	(524.88)	69.50	162.24	(278.94)	170.97	(279.61)
12	Extraordinary items (net of tax expense Rs Lakhs)	-	-	-	-	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11 ± 12)	8.32	73.70	(328.09)	(39.48)	(524.88)	69.50	162.24	(278.94)	170.97	(279.61)
14	Share of Profit / (loss) of associates*	-	-	-	-	-	-	-	-	-	-
15	Minority Interest *	-	-	-	-	-	0.10	0.18	0.16	0.42	0.49
16	Net Profit / (Loss) after taxes, Minority interest and share of profit / (loss) of associates (13 $\pm$ 14 $\pm$ 15) *	8.32	73.70	(328.09)	(39.48)	(524.88)	69.40	162.06	(279.10)	170.55	(280.10)
17	Paid-up equity share capital (Face Value of the share Rs. 10)	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-		-		-	-		-
19.i	Earning per share (before extraordinary items) (of Rs. 10/-each) (not annualised)										
	(a) Basic (b) Diluted	0.10 0.10	0.87 0.87	(3.86) (3.86)	(0.46) (0.46)	(6.17) (6.17)	0.82 0.82	1.91 1.91	(3.28) (3.28)	2.01 2.01	(3.29) (3.29)
19.ii	Earning per share (after extraordinary items) (of Rs. 10/-each) (not annualised)										
	(a) Basic (b) Diluted	0.10 0.10	0.87 0.87	(3.86) (3.86)	(0.46) (0.46)	(6.17) (6.17)	0.82 0.82	1.91 1.91	(3.28) (3.28)	2.01 2.01	(3.29) (3.29)

PAR		Current Quarter Ended 31.03.2013	Previous Quarter ended 31.12.2012	Corresponding Quarter Ended 31.03.2012	Current Year Ended 31.03.2013	Previous Year 31.03.2012
A 1	PARTICULARS OF SHAREHOLDING Public shareholding - Number of shares - Percentage of shareholding	32,94,950 38.74	32,94,950 38.74	32,94,950 38.74	32,94,950 38.74	32,94,950 38.74
2	Promoter and Promoter Group Shareholding **  a) Pledged / Encumbered  - Number of shares  - Percentage of shares (as a % of the total shareholding of promoter and promoter	7,81,488 15.00	7,81,488 15.00	0 -	7,81,488 15.00	- -
	group) - Percentage of shares (as a % of the total share capital of the company) b) Non - encumbered	9.19	9.19	-	9.19	-
	<ul> <li>Number of shares</li> <li>Percentage of shares (as a % of the total shareholding of promoter and promoter group)</li> </ul>	44,28,428 85.00	44,28,428 85.00	52,09,916 100.00	44,28,428 85.00	52,09,916 100.00
	Percentage of shares (as a % of the total share capital of the company)	52.07	52.07	61.26	52.07	61.26

	PARTICUALRS	
В	INVESTOR COMPLAINTS	
		31.03.2013
	Pending at the beginning of the quarter	NIL
	Received during the quarter	NIL
	Disposed of during the quarter	NIL
	Remaining unresolved at the end of the quarter	NIL

			-1			
		Standalone		Consolidated		
		Year End		Year End		
	FOURTY AND LIABILITIES	31.03.2013	31.03.2012	31.03.2013	31.03.20	
	EQUITY AND LIABILITIES					
1	Shareholders' funds					
	Share capital	850.49	850.49	850.49	85	
	Reserves and surplus	652.70	692.18	990.21	95	
	Money received against share warrants	-	002.10	000.21		
(-)	Sub-total - Shareholders' funds	1,503.19	1,542.67	1,840.70	1,80	
2	Share application money pending allotment	-				
3	Minority interest*	-		2.94		
	Non-current liabilities					
	Long-term borrowings	1,353.37	875.01	1,590.09	1,28	
	Deferred tax liabilities (net)	1,333.37	073.01	1,590.09	1,20	
	Other long-term liabilities			100.55		
	Long-term provisions	_				
(u)	Sub-total - Non-current liabilities	1,353.37	875.01	1,698.64	1,28	
	Sub-total - Non-Current nabilities	1,555.57	073.01	1,030.04	1,20	
	Current liabilities					
	Short-term borrowings	226.03	761.92	739.58	1,30	
	Trade Payables	734.56	648.39	1,256.74	1,30	
	Other current liabilities	56.59	44.61	422.81	29	
(d)	Short-term provisions			69.67	4	
	Sub-total - Current liabilities	1,017.18	1,454.92	2,488.80	2,95	
	TOTAL - EQUITY AND LIABILITIES	3,873.74	3,872.60	6,031.08	6,05	
В	ASSETS		-	·	•	
1	Non-current assets					
	Fixed assets	865.26	930.26	3,271.25	3,33	
_ ,	Goodwill on consolidation *		000.20	0,27 1.20	0,00	
	Non-current investments	1,071.45	1,069.32	73.44	7	
. ,	Deferred tax assets (net)	121.37	113.44	-	11:	
	Long-term loans and advances	180.36	344.22	194.33	35	
	Other non-current asstes	1.86	2.52	1.86		
(1)	Sub-total - Non-current Assets	2,240.30	2,459.76	3,540.88	3,87	
2	Current assets					
	Current Investments	-				
_ ` '	Inventories	297.51	476.91	634.20	68	
	Trade receivables	1,036.43	655.82	1,374.28	1,12	
	Cash and cash equivalents	25.32	(30.61)	57.58	(6	
	Short-term loans and advances	274.18	310.72	424.14	43	
	Other current asstes					
١٠/	Sub-total - Current Assets	1,633.44	1,412.84	2,490.20	2,17	
	Sub-total - Current Assets	1,033.44	1,712.07	2,430.20	2,17	

Notes:	
1 The	above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 28, 2013
2 The	Company has opted to submit Standalone as well as Consolidated financial statements. The Consolidated financial results comprise the results of Parnax Lab Limited and One Subsidiary Company
3 Purs	uant to approval of Registrar of Companies, Mumbai, the name of the Company is changed to Parnax Lab Ltd w.e.f April 2, 2012
	e there is no income, expenditure and net profit after tax from earlier activity, the figures provided above are from new line of business i.e. Pharmaceutical Activity. figures of the last quarter are balancing figures between audited figures in respect to full financial year upto March 31, 2013 and the unaudited published year to date figures upto December 31,
	2 being the date of the end of third quarter of the financial year which were subject to limited review.
6 The	Conolidated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notiifed by Companies Accounting Standards Rules, 2006
7 Figu	res pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.
8 EPS	for quarter ended is on non annualised basis.
9 The	Company is dealing into one segment : Dealing in Pharmaceutical Formulations
	FOR PARNAX LAB LIMITE

1111198

DATE: 28.05.2013

PLACE: MUMBAI CHAIRMAN & WHOLE TIME DIRECTOR